• Peng-Jun Lu, Walter W Williams, Jun Li, Christina Dorell, David Yankey, Deanna Kepka, and Eileen F Dunne.
• Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC, Atlanta, Georgia. Electronic address: lhp8@cdc.gov.
• Am J Prev Med. 2013 Apr 1; 44 (4): 330338330-338.

BackgroundIn 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9-26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group.PurposeTo assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV vaccine, and identify factors independently associated with such awareness among men aged 18-26 years.MethodsData from the 2010 National Health Interview Survey were analyzed in 2011.ResultsIn 2010, HPV vaccination initiation among men aged 18-26 years was 1.1%. Among the 1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a higher likelihood of awareness of both HPV and HPV vaccine among men aged 18-26 years included having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician contacts; private health insurance; received other vaccines; and reported risk behaviors related to sexually transmitted diseases, including HIV.ConclusionsHPV vaccination initiation among men aged 18-26 years in 2010 was low. HPV and HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP published a recommendation for routine use of HPV4 among men/boys in December 2011, continued monitoring of HPV vaccination uptake among men aged 18-26 years is useful for evaluating the vaccination campaigns, and planning and implementing strategies to increase coverage.Published by Elsevier Inc.

16 keywords...

hide…